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I Introduction and objective of this report
This report provides an update on infectious diseases 
related to drug use in Europe for the period up to June 
2016. It covers the most recent data both on infectious 
diseases among people who inject drugs in Europe, 
collected with the EMCDDA Drug-related infectious 
diseases (DRID) indicator, and on the responses in the 
area. It includes highlights and new findings discussed 
during the DRID indicator’s annual expert meeting, held in 
Lisbon on 6–8 June 2016. This event offered a platform for 
discussion among experts from the 28 EU Member States, 
Norway and Turkey. EU agency partners and international 
organisations were also represented (1). Annual network 
meetings primarily aim to share and discuss the analysis of 
national and European data and new developments, and 
their implications for actions and policy development. It 
should be noted that as the publication is, in part, based 
on the presentations to the meeting, some of the 
information presented here is necessarily preliminary.
(1) Information on the meeting including the agenda, Preliminary summary 
and highlights, presentations and supporting documents is available at the 
DRID meeting webpage.
Injecting. The majority of people who inject drugs in 
Europe are heroin users. Recent national estimates 
(from 2008 onwards) of the prevalence of injecting drug 
use are available for only 16 of the 30 countries 
reporting to the EMCDDA. The estimates range from 
less than 1 to more than 9 cases per 1 000 population 
aged 15–64. A downward trend can be observed in the 
proportion of injectors among those entering 
specialised drug treatment for heroin-related problems 
for the first time in their life (from 43 % in 2006 to 33 % 
in 2014), but levels of injecting remain high among 
stimulant users, and is a cause of particular concern.
Hepatitis C virus (HCV). HCV is the most prevalent 
blood-borne virus infection among people who inject 
drugs. In six of the 13 countries with national prevalence 
data for this population, rates were reported to be in 
excess of 50 %. Among countries with national trend 
data (2008–14), statistically significant (p<0.05) 
increases were reported in five (Greece, Latvia, Hungary, 
Slovenia and Turkey).
Human immunodeficiency virus (HIV). The European 
Union is seeing a continuing decline in the number of 
new HIV infections attributed to injecting drug use, with 
the 1 236 cases reported in 2014 being the lowest for 
a decade. Nevertheless, the number of new HIV cases 
and the levels of prevalence among people who inject 
drugs remain high in a number of countries, particularly 
Estonia, Latvia and Lithuania.
New local HIV outbreaks. Local HIV outbreaks among 
marginalised groups of injectors in Dublin (Ireland), 
Glasgow (United Kingdom) and Luxembourg are 
reported, and tailored prevention measures are required 
in these cases. Specific potential risk factors for HIV 
transmission among people who inject drugs have been 
identified in several countries, primarily associated with 
certain risk behaviours (the sharing of injection 
equipment) and lack of intervention coverage.
HCV continuum of care. Due to the development of new 
effective medicines and a growing confidence that the 
treatment can be successfully offered to people who 
inject drugs, the HCV prevention and treatment 
response is building up in Europe, as reflected in the 
adoption of several national policy strategies and action 
plans. Although effective treatments are now available in 
Europe, provision is low and slowly scaling up. Ensuring 
good pathways into care will play an essential role in 
enabling drug injectors to access treatment.
Chemsex/slamming. The use of drugs to increase 
disinhibition and sexual arousal (chemsex) and, in 
particular, the injecting use of drugs in a sexual context 
(slamming) among a small minority of men who have 
sex with men has been linked to an increased risk of 
blood-borne infection transmission. Beyond harm 
reduction and treatment of infections, responses require 
a multidisciplinary approach to address the 
psychosocial aspects of drug taking behaviours as well 
as sexuality-related issues.
At a glance: a summary of key points 
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This report also draws on analysis of the information 
provided to the EMCDDA by the national focal points and 
their experts in the 2015 annual reporting exercise, the 
main findings of which are presented in the European Drug 
Report 2016 (EMCDDA, 2016a). The multi-indicator data 
set used in the analysis covers and integrates aspects of 
the epidemiology (prevalence of injection, prevalence of 
infections among people who inject drugs, notifications of 
newly diagnosed infections, harm, morbidity, outbreaks) 
and responses (prevention, infection testing, drug and 
infection treatments, and harm reduction).
I  Overview of the current situation: prevalence and trends in injecting, HIV and HCV infections
I  Overall decline in heroin injecting: but new patterns emerge
People who inject drugs are a key population affected by 
blood-borne viruses, in particular the human 
immunodeficiency virus (HIV) and hepatitis C and B viruses 
(HCV and HBV), as these infections can be transmitted 
through the sharing of syringes and other injection 
equipment. Recent national estimates (from 2008 
onwards) of the prevalence of injecting drug use, available 
for 16 countries, range from less than 1 to more than 9 
cases per 1 000 population aged 15–64 (Figure 1). The 
highest rates are reported from Latvia (9 cases per 1 000 
population) and the Czech Republic and Estonia (each with 
6 cases per 1 000 population).
Historically, in Europe overall, injection has been the main 
route of drug administration among heroin users, and this 
group has made up the majority of people who inject 
drugs. Information on people entering drug treatment for 
the first time in their life, however, shows a downward 
trend in the proportion of heroin users reporting injection 
as their usual route of drug administration, which fell from 
43 % in 2006 to 33 % in 2014. After heroin users, primary 
users of amphetamines are the second largest group of 
injectors among first-time treatment entrants. 
Nevertheless, among first-time clients with amphetamines 
as their primary drug, 47 % reported injecting as their 
main route of administration, representing a small 
increase since 2006. The injection of stimulants raises 
particular public health concerns, as these short-acting 
drugs are often associated with a high frequency of 
injection.
FIGURE 1
Prevalence estimates of injecting drug use (2008–14 data)
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Methods: CR, capture–recapture; CM, combined method; TM, treatment multiplier; TP, truncated Poisson; OT, other; HM, HIV multiplier; MM, mortality 
multiplier. See also Appendix 1.
Source: EMCDDA Statistical Bulletin 2016.
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I HCV infections: prevalence and trends
In sero-prevalence studies among people who inject drugs 
conducted in 2013–14, HCV antibodies — indicating 
present or past infection — were found in between 15 % 
and 84 % of cases, with most studies showing rates in 
excess of 50 % (Figure 2). The high overall level of 
prevalence is likely to have important long-term 
consequences, as HCV infection, often worsened by heavy 
alcohol use, accounts for increasing numbers of cases of 
liver disease, including cirrhosis and liver cancer, and 
increasing numbers of deaths, among an ageing 
population of high-risk drug users. Many of those with the 
virus are still undiagnosed, with studies suggesting that in 
Europe between 24 % and 76 % are unaware of their 
infection status (Wiessing et al., 2014).
Among countries with national trend data (2008–14), 
statistically significant (p < 0.05) increases were reported 
in five (Greece, Latvia, Hungary, Slovenia and Turkey).
In the period 2012–14, statistically significant local or 
national increases of HCV antibody prevalence have been 
documented among people who inject drugs in Austria, 
Greece, Hungary and Slovenia.
Furthermore, there is evidence of significant longer-term 
(since 2008) increases at subnational level in Bulgaria and 
Latvia (most-recent HCV antibody prevalence among drug 
users respectively estimated at 67 % (Sofia, 2014), 79 % 
(8 Bulgarian cities, 2012) and 84 % (6 Latvian cities, 
2013)), which — despite some signs of stabilisation or 
even decrease in recent years — point to continuing high 
levels of risk behaviour among people who inject drugs. Big 
increases in HCV prevalence were observed in Turkey 
since 2008, with prevalence now standing at a medium 
level (most-recent HCV antibody prevalence among 
injectors estimated at 43 %) (EMCDDA, 2016c).
Prevalence of HCV antibodies in people who inject drugs 
under 25 years of age (young injectors) and in those who 
have been injecting for less than 2 years (new injectors) 
can be used as indicators of recent infection or incidence. 
Current, and in some cases high levels of, transmission of 
HCV are found among young or new injectors in nine of the 
16 countries with sufficient data available for at least one 
of these groups. These results also suggest that HCV 
infection is often acquired relatively early in an individual’s 
injecting career (see also section ‘HIV risk among people 
who inject drugs’).
FIGURE 2
HCV antibody prevalence among people who inject drugs in the European Union, Norway and Turkey, from national and 
local studies, 2013–14
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I  HIV notifications, late diagnosis, prevalence and outbreaks
Notifications
Although HIV infection is preventable through effective 
public health measures, transmission due to injecting drug 
use continues in Europe, especially in eastern counties. In 
the European Economic Area (the EU, Iceland, 
Liechtenstein and Norway), an overall decline in the 
transmission of the virus through injecting drug use has 
been documented, and in 2014 only 4 % of all newly 
reported HIV diagnoses in these 31 European countries 
were attributed to injecting (ECDC and WHO, 2015).
Over the past decade, the average rate of HIV cases 
attributed to injecting drug use in the European Union 
more than halved (from 5.6 cases per million population in 
2005 to 2.4 in 2014). This overall declining trend was 
interrupted in 2011/12, when a significant increase in new 
infections occurred due to localised outbreaks in Athens 
and Bucharest (Figure 3). Some EU countries, however, 
report much higher numbers of HIV cases attributed to 
injecting drug use per million population. In Estonia, there 
were 51 newly reported HIV cases attributed to injecting 
drug use per million population in 2014 — 21 times the EU 
average. Rates of newly reported HIV attributed to 
injecting drug use were also high in Latvia (37 cases per 
million population), Luxembourg (29), Lithuania (13), 
Greece (9), Romania (8) and Bulgaria (6) (see also the 
section ‘Update on HIV outbreaks’, below).
FIGURE 3
Number of newly diagnosed HIV cases in persons infected 
through injecting drug use in the 28 EU Member States, 
Norway and Turkey
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Source: ECDC and WHO, 2015
Late diagnosis remains a serious problem
In 2014, 60 % of newly notified injecting-related 
transmissions of HIV in the European Economic Area (2) 
were diagnosed late (<350 cells/mm3) (ECDC and WHO, 
2015). This highlights a clear need to extend existing 
testing programmes in order to prevent harms related to 
late diagnosis, such as increased morbidity and mortality, 
higher health costs and more transmission.
(2) Based on 827 cases where CD4 cell count data is available. 
The use of synthetic cathinones by injection was first 
noted in Hungary in 2010 (Peterfi et al., 2014). While 
until 2010, nearly all clients attending needle and 
syringe programmes injected either heroin or 
amphetamines, these drugs were complemented and 
replaced by synthetic cathinones, and other synthetic 
stimulants, some of which appeared and disappeared 
one after another (Rácz et al., 2016). In parallel, HCV 
prevalence trends among people who inject drugs in 
Hungary increased (Gyarmathy and Sárosi, 2015; Tarján 
et al., 2015). Within the past three reporting years 
(2011–14), national HCV prevalence rates among people 
who inject drugs doubled, while over the same period, 
prevalence levels in Budapest increased from around 
35 % to 60 %. Preliminary data for 2015 indicate further 
increases among injectors outside the capital, pointing 
to ongoing high levels of risk behaviours (Horváth and 
Tarján, 2016). Prevention measures in Budapest were 
set back when the two largest needle and syringe 
programmes — distributing more than half of the total 
national volume of syringes — were closed, leading to 
a considerable decrease in the provision of sterile 
injection equipment and in the number of clients 
covered by the intervention (Horváth and Tarján, 2016).
Impact of drug market changes on drug use patterns: the example of Hungary
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Prevalence
Recent estimates (2013–14) of HIV prevalence among 
people who inject drugs are available for 27 of the 30 
EMCDDA countries (25 of the EU Member States, 
excluding Denmark, France and Ireland, and Norway and 
Turkey). While the prevalence of HIV infection among 
people who inject drugs is currently below 5 % in most of 
the countries, prevalence levels of 5 to 10 % are reported 
from national studies carried out in Greece and from 
national and subnational studies in Belgium and Germany. 
HIV prevalence of more than 10 % is found among 
populations of drug injectors in Italy, Portugal and Spain, 
which are among the countries where HIV entered 
injecting drug-using populations very early, before effective 
prevention measures were put in place and effective 
treatment was available. These rates represent 
predominantly ‘old’ infections.
A different situation prevails in Lithuania, Latvia and 
Estonia (see also section ‘HIV risk among people who 
inject drugs’): data from a three-city study in Lithuania 
show levels of 12.5 % HIV prevalence, and in some local 
studies among injectors in Latvia (Riga) and Estonia 
(Narva) rates exceed 25 %. In addition, the number of 
newly reported cases in all three countries remains high, 
signalling ongoing transmission.
Update on HIV outbreaks
The HIV situation and response in Greece and Romania 
have improved and the numbers of new HIV cases have 
declined since the 2011/12 outbreaks, with preliminary 
data for 2015 suggesting further decreases. In the case of 
Romania, however, 91 of the 149 new HIV cases reported 
in 2015 (61%) were diagnosed with AIDS at the time of 
notification, pointing to a lack of screening and early 
diagnosis. New local outbreaks were reported from three 
cities in western Europe: Glasgow (United Kingdom), 
Luxembourg and Dublin (Ireland).
A large HIV outbreak was reported in Glasgow (United 
Kingdom), with 47 new diagnoses among people who 
inject drugs in 2015 and 16 new cases diagnosed in the 
first 6 months of 2016. Most of the cases had already 
been in contact with drug and social services in 
connection with other serious health and social problems. 
Drug injection is a risk factor for other infectious 
diseases including tetanus and botulism. Clusters and 
sporadic cases of wound botulism among injecting drug 
users had previously been reported in EU countries and 
Norway between 2013 and 2015. Since the beginning of 
2016, there have been two confirmed and one 
suspected case of wound botulism among people who 
inject drugs in Germany (ECDC, 2016c) and four in the 
United Kingdom. There is no confirmation about 
a common source, but these events may indicate that 
a batch of heroin was contaminated with spores of the 
anaerobic bacterium Clostridium botulinum. Bacterial 
injection site infections are also common, with a large 
outbreak of soft tissue infections reported in Scotland in 
2015. A cluster of four cases of Bacillus cereus infection 
among injectors (mainly of amphetamine) was reported 
between December 2015 and April 2016 in Norway. 
Following an outbreak of HBV infection in eight counties 
in Sweden, which had started in 2014 and affected 38 
injectors and their sexual partners, responses included 
a free HBV vaccination campaign and the opening of 
three new needle and syringe programmes.
The lack of immunisation coverage among drug users 
and other marginalised groups was documented in the 
context of a hepatitis A virus outbreak in the Czech 
Republic. In the Cheb region (32 000 inhabitants), a total 
of 339 notifications of viral hepatitis A infection were 
recorded by June 2016 in an outbreak that had started 
in 2014. More than a third of the cases (114, 34 %) were 
drug users, and a significant minority (35, 10 %) was 
without stable housing. In response, the city decided to 
pull down an abandoned building which had served as 
‘unofficial’ shelter for homeless people, including drug 
users. The local harm reduction centre increased its 
prevention and health promotion activities among the 
homeless population, through outreach activities on the 
street and in cooperation with epidemiologists. 
Vaccination of over-18s in the general population (two 
doses, if susceptible and no history of vaccination) is 
recommended in the Czech Republic and is mandatory 
for specific at-risk groups, such as healthcare 
professionals (ECDC, 2016b), however funding for 
a targeted vaccination campaign among the homeless 
and at-risk population in Cheb could not yet be secured.
Bacterial infections, viral hepatitis (B and A) outbreaks
9Update from the EMCDDA expert network I November 2016
Factors possibly associated with the outbreak include low 
awareness of HIV risk, poverty and homelessness, cocaine 
injecting, specific batch preparation and injecting 
practices.
In Luxembourg, after an initial alert issued by the 
supervised injection facility, an outbreak of HIV infections 
among injecting drug users was identified. Fifty-one new 
cases were identified between January 2013 and April 
2016. Most of the newly infected have been attending 
low-threshold drug services over the past 10 years, but 
had otherwise poor linkage to care. Many were HCV 
co-infected, and all reported having recently injected 
cocaine, which had become more available on the illicit 
market.
Following a dramatic rise in reported new HIV cases 
among homeless drug users in Dublin in 2015 (Giese et al., 
2015), a multidisciplinary team assessed the outbreak, 
tracing its beginning back to September 2014 and linking it 
to the injection of a synthetic cathinone alpha-PVP 
(‘snow-blow’), which may have contributed to a chaotic 
lifestyle, resulting in the sharing of injecting equipment 
and unsafe sex, the primary routes for transmission. 
Prevention measures and outreach work targeting 
marginalised drug users are currently being increased.
More generally, regional differences in drug use patterns 
and increases in stimulant injecting — for example, more 
crystal meth injection in eastern parts of Germany; and the 
emergence of injection of the short-acting stimulant 
mephedrone (4-methylmethcathione) among higher-risk or 
more vulnerable groups in the United Kingdom (Hope et al., 
2016) — were highlighted throughout the meeting, and 
were linked to a higher risk and potential for incidents and 
to clusters of injecting-related infections.
I HIV risk among people who inject drugs
The most recent data on HIV notifications and trends in 
prevalence (HIV-related indicators) were analysed in 
combination with indicators of transmission risk and 
intervention coverage to determine the potential risk for 
HIV outbreaks among people who inject drugs in each 
country (see Appendix 2).
The three groups of indicators comprised the following:
• HIV-related indicators: HIV case notifications, and HIV 
prevalence and trends 2008–14 among people who 
inject drugs;
• Transmission risk: prevalence of injecting drug use, and 
HCV prevalence and trends 2008–14 among people 
who inject drugs;
• Intervention coverage: coverage rates of opioid 
substitution treatment and needle and syringe 
programmes.
HIV-related indicators highlighted eight countries: the 
three Baltic States, Bulgaria, Greece, Ireland, Luxembourg 
and Romania.
HCV prevalence among injecting drug users of more than 
60 %, or recent significant increases in HCV prevalence, 
was found in 12 countries (see Appendix 2); in nine of 
them (Austria, Bulgaria, Estonia, Finland, Germany, Greece, 
Hungary, Latvia and Lithuania) high or increasing HCV 
prevalence among young or new users — a signal of 
ongoing injecting risk behaviour — was also documented 
(EMCDDA, 2016c). Elevated prevalence of injecting was 
documented the Czech Republic and Latvia (>6 per 1 000 
adult inhabitants).
Low coverage of both intervention indicators (coverage of 
opioid substitution treatment and needle and syringe 
programmes) was reported from Cyprus, Hungary, Latvia 
and Slovakia, and seven other countries reported low 
coverage of one of the interventions (see Appendix 2).
Compared with the previous assessment (EMCDDA, 
2015), some improvements in data availability can be 
noted. However, the absence of estimates of the size of the 
population injecting drugs prevents a fuller assessment of 
transmission risks and intervention coverage in some 
countries: in particular in Austria, Bulgaria, Germany, 
Lithuania and Romania.
Local studies in eight Bulgarian cities documented 
ongoing risk behaviour, with increases in HCV prevalence 
among people who inject drugs over several years (2008–
13). In addition, the number of HIV notifications increased 
in 2014, reversing the long-term declining trend observed 
since 2009.
In Hungary, HCV transmission continues at increased rates 
(see also the box ‘Impact of drug market changes on drug 
use patterns: the example of Hungary’).
Overall, the results of the 2016 risk assessment and recent 
outbreaks underline both the need for continued vigilance 
and the necessity to maintain prevention measures at high 
levels of coverage in order to keep HIV infection low among 
injecting drug users in the European Union.
10
Drug-related infectious diseases in Europe
I  Tailoring infectious disease prevention measures to the needs of vulnerable groups
I Homelessness and public injecting
The recent HIV outbreaks in Dublin, Glasgow and 
Luxembourg share a number of common elements. Many of 
the newly infected were in contact with drug treatment 
services, but continued to experience various health 
problems, marginalisation and criminal justice issues. Within 
the context of the outbreaks in Ireland and the United 
Kingdom, experts discussed the precarious social and living 
circumstances of the long-term injectors affected, referring 
to a ‘homelessness crisis’ in Ireland, and the high level of 
homelessness, poverty and prison history among people 
who inject drugs in Glasgow. Injecting in public spaces, 
which may be associated with an increased risk of infection, 
was also common among the new HIV cases. Discussions 
between public health stakeholders about the establishment 
of supervised drug consumption facilities for vulnerable 
groups of injectors are ongoing in Ireland and Scotland.
I  Using mail services to improve geographical coverage of syringe provision
In France, an innovative model of provision of syringes and 
other injecting equipment, introduced in 2011, uses the 
mail service to deliver injecting equipment. This service is 
managed by the national harm reduction association SAFE 
(a service provider specialised in the design and 
distribution of prevention kits via syringe machines) and is 
a response to difficulties expressed by drug users in 
smaller towns or villages to obtain sterile injecting 
equipment, and to needs expressed on internet forums. 
Participants in the mail scheme receive a personalised 
package of sterile syringes and other clean drug-use 
material together with information on counselling and 
treatment centres. In 2015, the service dispatched 1 400 
postal packages containing a total of 240 000 syringes to 
480 clients. A qualitative survey among users found 
evidence of positive effects, such as a reduction in re-use 
and sharing of materials, and that the main reasons to use 
the service are geographical distance, mobility 
impairments or the need for specific material (such as 
wheel filters, ascorbic acid) (see also Figure 4) that are not 
available in all low-threshold centres. The annual cost per 
user is estimated to be EUR 615. While the experiment is 
deemed a success, multi-annual funding has not yet been 
secured.
I Addressing the needs of migrants
A new ECDC report estimates the chronic viral hepatitis 
burden in terms of infected cases among first-generation 
migrants in European Economic Area countries, based on 
best available data sources, in order to support countries 
FIGURE 4
Examples of injecting equipment that can be sent to clients of the French harm reduction service SAFE
Source: Association SAFE. http://www.rdr-a-distance.info/index.php/materiels-proposes
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to target prevention and screening efforts towards those 
migrant groups who would benefit most (ECDC, 2016d). 
While there are wide ranges around the estimates 
presented, the comparison of prevalence data from 
studies in migrants with estimates for the in-country 
prevalence showed that the prevalence in migrant 
populations is often lower, especially for chronic hepatitis 
B. The report points out that the main bottleneck in 
providing treatment to this group is case detection and 
stresses the need for good information on levels of 
infection among this group in order to inform policy-
making and healthcare planning.
Homelessness may put migrants at risk of drug-related 
infections. In Catalonia (Spain), a cross-sectional study 
among 761 drug injectors visiting harm reduction centres 
in 2010–11 found that more than one in five (21.4 %) had 
been injecting for less than 5 years and that most of the 
new injectors (59 %) were immigrants. Among new 
injectors, HIV and HCV prevalence was 20.6 % and 59.4 %, 
and HIV and HCV incidence was estimated at 8.7 and 25.1 
per 100 person-years, respectively. This study found that 
HIV infection among new injectors was associated with 
homelessness and reporting a previous sexually 
transmitted infection. Compared with those with longer 
injecting careers, the prevalence of syringe sharing was 
lower among the new injectors, but the sharing of other 
injecting equipment was more frequent. It was concluded 
that tailored measures to prevent infectious diseases are 
needed and that cultural and language issues impeding 
access to care needed to be addressed (Folch et al., 2016).
In 2015, the Health Protection Surveillance Centre in 
Ireland published new guidelines to offer best practice 
advice in relation to assessment of common infectious 
diseases in migrants. The guidelines are intended for use 
by any healthcare professional involved in consultation 
with migrants in settings such as primary care, specialist 
services for migrants, antenatal clinics, prison medical 
services or hospitals. The guidelines are intended to 
facilitate opportunistic assessment and do not constitute 
a formal screening programme. Participation on the part of 
the migrant is on a voluntary basis (Health Protection 
Surveillance Centre, 2015).
I Factors associated with undiagnosed infection
In order to better inform case finding, factors associated 
with undiagnosed HIV infection among people who inject 
drugs have been explored using data from the unlinked 
anonymous monitoring surveys of infections and risk 
among people who inject drugs in the United Kingdom. 
Participants in this survey are recruited through specialist 
services (such as needle and syringe programmes and 
addiction treatment) in around 60 sentinel areas (Public 
Health England, 2016). Data for the period 2005–14, 
covering 25 743 first participations of people who inject 
drugs in the study, were analysed. Over a quarter (28 %) 
reported never being tested for HIV. Among the first 
participations, 318 were infected with HIV (overall 
prevalence 1.2 %; 4 % in London, 0. 7% elsewhere). Where 
information was available, 29 % of those infected with HIV 
(86/298) were probably undiagnosed. Compared with 
those whose HIV infection was diagnosed, those with 
undiagnosed HIV infection were younger (32 years 
compared to 38.5), more often recruited outside London 
(adjusted odds ratio, AOR, 2), less likely to have had 
a hepatitis C test (AOR 2.7) and they were more likely to be 
women not currently sexually active (AOR 4.5).
Comparing those with undiagnosed HIV to those who were 
HIV-negative showed that those with undiagnosed 
infections were younger (32 versus 34 years), more often 
diagnosed in London (AOR 2.6) and more often born 
outside the United Kingdom (AOR 3.0).
Though these findings should be interpreted with 
caution — as many of the undiagnosed infections were 
from the earlier years of the study period — they indicate 
a need to improve the uptake of HIV testing.
I  Chemsex and slamming: off the radar of typical drug services?
‘Chemsex’ is an increasingly used term to define sex 
between men that occurs under the influence of drugs 
taken immediately preceding or during the sexual session 
(Bourne et al., 2014). Among men who have sex with men, 
the injection or so-called ‘slamming’ of drugs — including 
gamma-hydroxybutyrate and gamma-butyrolactone (GHB/
GBL), methamphetamine, cocaine, mephedrone and new 
psychoactive substances — is associated with chemsex.
Unsafe drug use practices, namely injecting and sharing, 
have been reported and investigated among men who 
have sex with men in France, Germany, the Netherlands, 
Spain and the United Kingdom, and signals of this have 
been picked up in other European countries. However, 
levels and patterns of use are culturally determined and 
variable. Available data suggest that only a small minority 
of gay men use drugs on a regular basis, and only 
a minority of those do so in a sexual context. However, 
harm related to slamming (injecting) can be severe, 
including HIV and HCV infections. Recent studies carried 
out by the French network of Pharmacovigilance and 
Addictovigilance Centres found that, in some cases, 
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additional complications also developed such as 
psychiatric disorders (psychotic symptoms, agitation, 
anxiety, suicidal ideas or attempts), acute intoxications 
and dependence.
Responding to this practice will require a multidisciplinary 
approach, improved collaboration and acquisition of 
cross-disciplinary competencies in sexual health 
counselling services and the drugs field.
I HCV treatment and continuum of care
I A changing treatment landscape
Information on route of transmission is available for 
approximately 16 % (0–79%) of all HCV notifications in the 
European Union in 2014. Among these, 80 % of newly 
reported chronic HCV infections are linked to injecting 
drug use (ECDC 2016a). This makes it likely that current 
injectors as well as those who have injected in the past 
carry a very high burden of HCV infection and thus are 
a key target group for HCV treatment. The HCV treatment 
landscape is changing with the development of very 
effective antiviral drugs. Effective treatments are now 
available in Europe, but provision is low and slowly scaling 
up. The main challenges are low levels of testing, high 
treatment costs and unclear referral and treatment 
pathways in many countries (EMCDDA, 2016b).
I New hepatitis C strategies and action plans
WHO elimination of HCV. The first ever Global Health 
Sector Strategy for Viral Hepatitis (2016–21), adopted in 
May 2016, aims at the elimination of viral hepatitis as 
a major public health threat by 2030. The impact targets 
for the ‘elimination’ of viral hepatitis in relation to HBV and 
HCV, the forms most closely associated with injecting drug 
use, are a reduction in the number of new cases of chronic 
infection from current levels of 6–10 million worldwide 
(2015) to 900 000 in 2030, with a reduction in deaths from 
1.4 million to under 500 000 (Figure 5). In consultation 
with European governments, civil society, academic 
experts and partner organisations including the EMCDDA 
and ECDC, a regional action plan for the health sector 
response in the WHO European Region has been 
developed. The EMCDDA and ECDC will support the 
strategy by contributing to monitoring its implementation 
and the achievement of the regional targets.
Several European countries are defining new viral hepatitis 
strategies or revising existing ones. News about national 
HCV strategies and action plans that specifically address 
people who inject drugs were reported from Denmark, 
France, Germany (BMG, 2016), Luxembourg, the 
Netherlands (see Figure 6) and Portugal. A review 
published in 2014 had identified existing HCV strategies in 
Austria, Denmark, Greece, Ireland, Lithuania, Norway, 
Slovenia and the United Kingdom (Maticic, 2014).
FIGURE 5
WHO vision and targets to tackle viral hepatitis: reduction in number of new chronic HBV and HCV infections and deaths
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I  New French guidelines prioritise immediate treatment of people who inject drugs
Under new guidelines by the French National Hepatology 
Society, access to hepatitis C treatment with direct-acting 
antivirals will be provided to everyone diagnosed with 
hepatitis C. Treatment should be immediate for patients 
diagnosed with stage 2 fibrosis and for chronic hepatitis 
C carriers waiting for a liver transplant or experiencing 
a recurrence of hepatitis C infection after a liver transplant, 
regardless of the stage of post-transplant fibrosis. It is 
recommended to grant immediate access to hepatitis 
C treatment also to groups at high risk of transmitting 
hepatitis C, including prisoners, migrants, pregnant women 
and people who inject drugs (AFEF, 2016).
I  Drug-related infectious disease news and updates
Less recruitment into injecting and fewer new HIV 
infections in Estonia. Investment in harm reduction 
services in Estonia included a significant scale-up of the 
number of sites providing injecting equipment (needles, 
syringes and alcohol wipes) and of the total number of 
syringes given out to people who inject drugs, which 
reached 2.4 million in 2010. The number of first-time 
visitors to these sites peaked in 2008, at more than 
4 000, but has decreased since then, indicating 
a deceleration in new injecting drug use. During the past 
five years (2011–15), the number of syringes given out 
levelled-off at around 2 million, while the number of new 
HIV infections detected at AIDS counselling centres and 
attributed (self-report) to injecting drug use fell from 69 to 
14 cases.
FIGURE 6
Revolution in HCV treatment
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Adapted from presentation by Esther Croes.
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Study confirms need to increase quality of screening. 
A respondent-driven study among 2 077 current injectors 
in eight large cities in Germany assessed infection risk 
behaviours and knowledge about HIV and HCV 
transmission risks, as well as infection status through 
biological markers and self-report (Wenz et al., 2016; 
Zimmermann et al., 2014). Comparing laboratory results 
with perceived status, 17 % of HIV-positive people who 
inject drugs and 27 % of those with chronic HCV infection 
were unaware of their infections (Nielsen et al., 2016). 
Further analysis showed an association between 
knowledge about risks of HCV transmission and avoiding 
these risks. Confusion and uncertainty among people who 
inject drugs regarding the meaning of a positive HCV test 
and HCV risk confirm the need to increase the quality of 
post-test counselling.
A new publication in the EMCDDA Insights series, 
Hepatitis C among drug users in Europe: epidemiology, 
treatment and prevention (EMCDDA, 2016b), provides 
a timely contribution to raising awareness of the hepatitis 
C epidemic in Europe and the opportunities now opening 
up to tackle this problem decisively. A state-of-the-art 
review of the epidemiology of the infection and an 
overview of the way preventive measures are currently 
implemented in European countries set the scene. 
International experts address the treatment of HCV 
infection among people who inject drugs, with an 
emphasis on how we encourage uptake and deliver 
effective outcomes. The new medicines and treatment 
regimens driving the transformation in the HCV treatment 
landscape are reviewed, and challenges of scaling up this 
treatment among drug using patients are explored (link).
Models of HCV care for the most vulnerable populations: 
HepCare Europe. The EU-funded project ‘HepCare Europe’ 
has embarked on developing models of HCV care for the 
most vulnerable populations, enhancing access to early 
diagnosis and treatment of viral hepatitis, in an integrated 
partnership between primary and secondary care. Service 
models to be tested in Bucharest, Dublin, London and 
Seville include outreach to the affected community 
providing point of care screening (oral HCV test) and 
linkage nurses, who provide community based testing 
(including fibroscan) to identify those in the more severe 
stages of disease (link).
New action plans for the health sector response to HIV 
and to viral hepatitis in the WHO European Region. The 
66th session of the WHO Regional Committee for Europe, 
in September 2016, endorsed the action plans, the 
implementation of which will rely on close cooperation 
between all key stakeholders, including the two EU 
agencies (link).
EU joint action on HIV and co-infection prevention and 
harm reduction (HA-REACT) addresses existing gaps in 
the prevention of HIV and other co-infections, especially 
tuberculosis and viral hepatitis, among people who inject 
drugs. This three-year project was launched in late 2015 
and brings together experts from most EU Member States. 
The HA-REACT Partnership Forum took place on 2–3 
November 2016, in Riga, Latvia. The closing event of 
HA-REACT will be held at the AIDS2018 conference in 
Amsterdam (link).
A project to develop evidence-based guidance on 
prevention of infectious diseases among newly arrived 
migrants to the European Economic Area has been 
initiated by ECDC. It aims to collect and synthesise the 
scientific evidence on screening and prevention of 
infectious diseases among migrants, review national and 
international policies, practices and guidelines in this field 
and draft guidance, in consultation with key experts 
working with migrants. The guidance is expected to be 
published in 2017.
Lisbon Addictions 2017. Abstract submission for the 
Second European Conference on Addictive Behaviours 
and Dependencies, to be held from 24 to 26 October 2017 
in Lisbon, is now open. More information is available from 
http://www.lisbonaddictions.eu.
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I Appendixes
I Appendix 1
Estimates of the prevalence of injecting drug use (rate per 1 000 population aged 15–64), last study available
Country Year
Injecting drug use prevalence 
(per 1 000 population aged 15–64)
Estimated number of users
Central Lower Upper
Central 
estimate
Lower bound Upper bound
Belgium 2014 3.48 2.43 4.92 25 295 17 638 35 699
Croatia 2012 0.44 0.35 0.61 1 274 998 1 746
Cyprus 2014 0.48 0.36 0.71 291 216 427
Czech Republic 2014 6.43 6.1 6.77 45 600 43 200 48 000
Estonia 2009 5.89 4.29 10.8 5 362 3 906 9 837
Finland 2012 4.6 4.1 6.7 15 611 13 770 22 665
Greece 2014 0.72 0.59 0.89 5 120 4 209 6 303
Hungary 2008–09 0.82 5 699
Latvia 2012 9.22 7.34 11.68 12 573 10 003 15 914
Luxembourg 2009 5.68 4.5 6.85 1 907 1 524 2 301
Netherlands 2008 0.22 0.21 0.22 2 390 2 336 2 444
Norway 2013 2.42 2.06 2.92 8 145 6 948 9 842
Portugal 2012 2.2 1.94 2.46 14 426 12 732 16 101
Spain 2013 0.3 0.24 0.37 9 879 7 971 11 786
Sweden 2008–11 1.31 8 021
United Kingdom 2004–11 3 2.87 3.22 122 894 117 370 131 869
NB: The estimates are based on several sources and statistical methods (e.g. capture–recapture, mortality multiplier) and not only on treatment data. They may 
underestimate the prevalence of injection, as some substances may not appear in the sources used (e.g. these estimates will not include image and perfor-
mance enhancing drugs). Caution is required when comparing countries. More information is available from http://www.emcdda.europa.eu/activities/hrdu 
Source: EMCDDA Statistical Bulletin 2016.
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| Appendix 2
HIV risk assessment 2016: Indicators of HIV situation, transmission risk and prevention coverage in 
30 European countries
HIV-related indicators Indicators of transmission risk Intervention coverage indicators
Country HIV cases (1) HIV prevalence trend
HCV prevalence: 
medium/high or 
increasing
Injecting drug use 
prevalence: high or 
increasing
Problem opioid 
users in substitution 
treatment (%)
Syringes distributed 
by specialised 
programmes (2) (per 
injecting drug user 
per year)
Austria 60 340–463
Belgium* 37
Bulgaria*
Croatia 64 154
Cyprus 16 1
Czech Republic 35 154
Denmark
Estonia* 2009 345
Finland* 2012 <30 290
France 76
Germany 50
Greece* 62 72
Hungary* 2008–09 23 81
Ireland* 46
Italy 37
Latvia 2012 8 33
Lithuania 13
Luxembourg* 2009 77 240
Malta 67
Netherlands 2008 65
Norway* 2013 45 261
Poland 17
Portugal 2012 75 150
Romania*
Slovakia* 8
Slovenia* 61
Spain* 2012 >50 230
Sweden 2008–11 25
Turkey*
United Kingdom* 2004–11 45
Low HIV notification 
rate (3)
No significant 
change in HIV 
prevalence (6)
HCV prevalence  
< 50 % or no 
significant 
decrease (9) 
Low injecting drug 
use prevalence 
(<3 ‰)
High intervention 
coverage (12) 
High intervention 
coverage (15)
Medium HIV 
notification rate (4)
Consistent 
non-significant rise 
in HIV prevalence (7)
HCV prevalence 
50–60 % or 
consistent 
non-significant 
rise (10)
Medium injecting 
drug use prevalence 
(3–6 ‰)
Medium intervention 
coverage (13)
Medium intervention 
coverage (16)
High HIV notification 
rate (5)
Significant increase 
in HIV prevalence (8)
HCV prevalence > 
60 % or significant 
increase (11) 
High injecting drug 
use prevalence  
(>6 ‰)
Low intervention 
coverage (14)
Low intervention 
coverage (17)
No information No information No information No information 
No information/ no 
recent population 
estimate
No information/ no 
recent population 
estimate
(1) Based on rates of newly diagnosed HIV infections with injecting drug use as mode of transmission per 100 000 general population. Source: ECDC, The 
European Surveillance System. 2014 HIV surveillance data are still preliminary and reporting delays are likely.
(2) Syringes given out by specialised needle and syringe programmes, not including pharmacy sales.
(3) Less than 5 cases per million population and no evidence of an increase in HIV case reports.
(4) 5–10 cases per million population or consistent but non-significant rise in rate at national level.
(5) More than 10 cases per million population or statistically significant increase in HIV case reports (95 % confidence level).
(6) No significant trend or statistically significant decrease of HIV prevalence. 
(7) Consistent but non-significant rise at national level.
(8) Statistically significant increase in HIV prevalence (95 % confidence level).
(9) National or subnational prevalence levels under 50 % or no significant trend or statistically significant decrease. 
(10) National or subnational prevalence levels between 50 % and 60 % or consistent but non-significant rise at national level. 
(11) National or subnational prevalence levels over 60 % or statistically significant increase in HCV prevalence (95 % confidence level).
(12) More than 50 % of estimated population in opioid substitution treatment.
(13) 30–50 % of estimated population in opioid substitution treatment.
(14) Less than 30 % of estimated population in opioid substitution treatment.
(15) More than 200 syringes per estimated injector.
(16) 100–200 syringes per estimated injector.
(17) Less than 100 syringes per estimated injector.
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(*) See notes below:
Belgium: A large study conducted each year since 2001 in a drug treatment centre in Antwerp found that HCV prevalence among injecting drug users 
exceeded 80 % from 2007 to 2011, but has decreased in more recent years.
Bulgaria: Two subnational studies among people who inject drugs, one in Sofia and another one in Sofia and seven other Bulgarian cities, showed increases in 
HIV prevalence in recent years compared to 2008 values. Overall, HCV prevalence among injecting drug users in eight Bulgarian cities increased between 2008 
and 2013, while a study carried out in Sofia alone found increases in HCV levels until 2012.
Estonia: Local studies found HIV prevalence rates among people who inject drugs of 61.8 % in Kothla-Jarve (2012) and 48 % in Narva (2014).
Finland: A national study measured HCV prevalence among injecting drug users at 74 % in 2012.
Greece: Studies indicate that although HIV prevalence among injecting drug users remains stable or may be decreasing, it is still much higher than the 
pre-epidemic level.
Hungary: A subnational study shows an increasing HCV prevalence trend between 2010 and 2013, although levels are still low (approx. 30 %). In 2014, HCV 
prevalence among injecting drug users reached 60.9 % in Budapest, the capital city, with a national level of 48.7 % prevalence. See Gyarmathy and Sarósi 
(2015). Ongoing increases in stimulant injecting in Hungary. See Tarján et al. (2015) and Rácz et al. (2016).
Ireland: Ongoing HIV outbreak in Dublin. See Giese et al. (2015).
Luxembourg: The city of Luxembourg is witnessing an HIV outbreak among injecting drug users since 2013.
Norway: The most recent national study (2014) found the HCV prevalence among injecting drug users to be 62.1 %, although a statistically significant decrease 
can be seen after 2008.
Romania: At 27.5 %, HIV prevalence among injecting drug users has dropped compared to the previous year, but still remains high relative to the pre-epidemic 
level.
Slovakia: Low needle and syringe programme coverage (Dublin reporting).
Slovenia: HCV prevalence among injecting drug users has been increasing since 2002 and has now reached 37 %.
Spain: Coverage of opioid substitution treatment is estimated at more than 50 % of the target population (source: Spanish national focal point).
Turkey: National HCV prevalence among injecting drug users in Turkey increased from 23.5 % in 2008 to 45.1 % in 2013, and fell to 42.8 % in 2014, with 
provisional 2015 data showing a further decrease. Free provision of sterile injecting equipment through needle and syringe programmes is not available in 
Turkey.
United Kingdom: Preliminary 2015 data for the Greater Glasgow and Clyde area in Scotland document a strong increase in the number of HIV case reports 
where injecting drug use is identified as the transmission route — from 15 cases per year or fewer (2006–14) to 47 cases in 2015.
Source: For estimates of HIV and HCV prevalence, number of opioid substitution treatment clients, number of syringes provided, and estimated size of injecting 
drug user and problem opioid user populations, EMCDDA Statistical Bulletin 2016.
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About this publication
Rapid communications bring you the latest findings 
and discussions in key areas in the drugs field. This 
report provides an update on infectious diseases 
related to injecting drug use in Europe. It covers both 
the EMCDDA Drug-related infectious diseases 
indicator, which collects data on the situation, and the 
responses in the area. The report is based on the 
indicator’s annual expert meeting, held in Lisbon in 
June 2016, which brought together national experts 
from the 28 EU Member States, Norway and Turkey.
About the EMCDDA
The European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) is the central source and 
confirmed authority on drug-related issues in Europe. 
For over 20 years, it has been collecting, analysing and 
disseminating scientifically sound information on drugs 
and drug addiction and their consequences, providing 
its audiences with an evidence-based picture of the 
drug phenomenon at European level.
The EMCDDA’s publications are a prime source of 
information for a wide range of audiences including: 
policymakers and their advisors; professionals and 
researchers working in the drugs field; and, more 
broadly, the media and general public. Based in Lisbon, 
the EMCDDA is one of the decentralised agencies of 
the European Union.
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